Regeneron, Sanofi-Aventis Initiate VEGF Trap Combination Study

Regeneron Pharmaceuticals and the sanofi-aventis Group have initiated a safety and tolerability study of the vascular endothelial growth factor (VEGF) trap in combination with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced solid malignancies.

This study is part of a series of single-agent and combination studies of the VEGF Trap in a variety of cancer types. Regeneron and sanofi-aventis are collaborating in the development and commercialization of the VEGF Trap in oncology.

The multicenter study will assess the safety, tolerability and pharmacokinetics of escalating doses of the VEGF Trap delivered intravenously. The study will include patients with solid malignancies that are metastatic or unresectable, and for which FOLFOX4 treatment is appropriate, such as metastatic colorectal cancer. In addition to safety and tolerability, the investigators will measure objective response rate, duration of response and time to tumor progression.